Induced Pluripotent Stem Cell (iPSC) Market Report 2026

The induced pluripotent stem cell (ipsc) market size has grown strongly in recent years. It will grow from $3.67 billion in 2025 to $4.02 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to breakthroughs in cellular reprogramming research, ethical concerns around embryonic stem cells, increased funding for stem cell research, growth of academic research collaborations, rising prevalence of chronic and degenerative diseases.

The induced pluripotent stem cell (ipsc) market size is expected to see strong growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expansion of regenerative medicine applications, increasing demand for personalized therapies, growing investment in cell and gene therapy, rising adoption of ipscs in neurological and cardiac research, favorable regulatory support for advanced therapies. Major trends in the forecast period include growing use of ipscs in disease modeling, increasing adoption in drug discovery and toxicity testing, expansion of patient-specific cell line development, rising focus on ethical alternatives to embryonic stem cells, advancements in reprogramming efficiency and cell stability.

The rising prevalence of neurological disorders is expected to drive the growth of the induced pluripotent stem cell (iPSC) market in the coming years. Neurological disorders are medical conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. Common examples include acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells provide opportunities to study disease mechanisms, facilitate drug testing, and offer insights into the causes of neurological disorders, while supporting the development of regenerative therapies for conditions such as Parkinson's and Alzheimer's disease. For instance, in October 2023, the World Federation of Neurology (WFN), a UK-based international nonprofit organization, reported that over 40% of the global population lived with a neurological condition, and the overall burden of neurological diseases is projected to nearly double by 2050. Therefore, the rising prevalence of neurological disorders is fueling the growth of the iPSC market.

Major companies in the iPSC market are collaborating to advance iPSC technology, enhancing regenerative medicine applications, improving disease modeling, accelerating drug discovery, and developing personalized therapeutic solutions. Induced pluripotent stem cell technology involves reprogramming adult somatic cells, such as skin or blood cells, back into a pluripotent state, enabling them to differentiate into any cell type in the body. For example, in April 2024, SCG Cell Therapy Pte Ltd, a Singapore-based biotechnology company, partnered with the Agency for Science, Technology and Research, a Singapore-based statutory board, to launch joint laboratories focused on advancing cellular immunotherapies. Supported by nearly S$30 million in funding, the initiative aims to develop scalable manufacturing processes for GMP-grade iPSC products, addressing challenges in translating laboratory innovations into clinically viable therapies.

In May 2024, Theragent Inc., a US-based biotechnology company, partnered with Pluristyx Inc. to expand its iPSC product portfolio. This partnership leverages Pluristyx’s expertise in providing induced pluripotent stem cell products, enabling Theragent to broaden its offerings in regenerative medicine. Pluristyx Inc. is a US-based biotechnology firm specializing in iPSC products.

Major companies operating in the induced pluripotent stem cell (ipsc) market are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, Parexel, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart.

North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2025. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the induced pluripotent stem cell (ipsc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the induced pluripotent stem cell market by increasing costs of laboratory equipment, reagents, and specialized consumables used in cell reprogramming and culture. These effects are most significant across drug discovery, regenerative medicine, and cell therapy segments, particularly in north america, europe, and asia-pacific regions reliant on imported research materials. Higher tariffs have raised operational costs for research laboratories and hospitals. However, tariffs are also encouraging local production of reagents, regional supplier development, and increased domestic research investments, strengthening long-term supply chain resilience.

The induced pluripotent stem cell (ipsc) market research report is one of a series of new reports that provides induced pluripotent stem cell (ipsc) market statistics, including induced pluripotent stem cell (ipsc) industry global market size, regional shares, competitors with a induced pluripotent stem cell (ipsc) market share, detailed induced pluripotent stem cell (ipsc) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (ipsc) industry. This induced pluripotent stem cell (ipsc) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Induced pluripotent stem cells (iPSCs) are regenerated stem cells derived from existing adult cells, such as hepatocytes, fibroblasts, keratinocytes, and neurons. The process involves introducing specific genes that reprogram the adult cell into a pluripotent state, enabling it to differentiate into any cell type in the body, such as heart, brain, or liver cells.

The main derived cell types from iPSCs include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes serve as the liver’s primary functional cells, carrying out a wide range of metabolic, endocrine, and secretory functions. These iPSC-derived cells find applications in academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized across various sectors, including hospitals and research laboratories.

The induced pluripotent stem cell (IPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.